Premium
Initial testing of aplidin by the pediatric pre‐clinical testing program
Author(s) -
Morton Christopher L.,
Houghton Peter J.,
Gorlick Richard,
Kolb E. Anders,
Lock Richard,
Carol Hernan,
Keir Stephen T.,
Reynolds C. Patrick,
Kang Min H.,
Maris John M.,
Billups Catherine,
Smith Malcolm A.
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21976
Subject(s) - medicine , in vivo , in vitro , oncology , pharmacology , microbiology and biotechnology , biology , biochemistry
Aplidin was tested in vitro at concentrations ranging from from 0.1 nM to 1.0 µM and in vivo at a dose of 0.6 mg/kg administered intraperitoneally on an every 4 days × 3‐schedule that was repeated at day 21. In vitro, Aplidin was most active against acute lymphoblastic leukemia (ALL) cell lines. In vivo, Aplidin induced significant differences in EFS distribution in 12 of 28 (43%) solid tumor models and 2 of 6 evaluable ALL models. Aplidin showed potent in vitro activity and induced significant in vivo tumor growth inhibition in some xenografts, but did not induce tumor regressions. Pediatr Blood Cancer 2009;53:509–512. © 2009 Wiley‐Liss, Inc.